Database to predict pancreatic cancer from IPMN

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to create a comprehensive database to track the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) to pancreatic cancer. It will utilize surgical pathology, radiology, and biochemical diagnosis to delineate the disease's progression. The study also seeks to outline management strategies for patients with IPMN, validate existing consensus guidelines, and identify potential risk factors associated with the progression to malignancy. By gathering and analyzing this data, the study hopes to improve early detection and treatment strategies for pancreatic cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients between the age of 18 and 90 years old who have been identified with a cystic mass consistent with IPMN on imaging

Exclusion Criteria:

* Patients who formally decline enrolment into the study

Where it's running

• St Vincent's Hospital Melbourne
  Fitzroy, Victoria, Australia Recruiting

Study contacts

• Principal investigator: Adrian Fox — St Vincent's Hospital Melbourne
• Study coordinator: Lynn Chong
• Email: lynn.chong@svha.org.au
• Phone: +61 3 9231 2074

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biophotonic blood test to spot pancreatic cancer risk in at‑risk adults

  A blood test using light-based technology is being tested to see if it can predict pancreatic cancer development in people at risk, and also check how well treatments work for those affected.

  Recruiting Fondazione Policlinico Universitario Campus Bio-Medico · Rome, Italy · NCT07659639

• AI-guided decision support for managing pancreatic conditions

  This project will test an AI tool that reads contrast-enhanced CT scans to help doctors decide whether people with suspected pancreatic disease need surgery, close monitoring, or routine follow-up.

  Recruiting Changhai Hospital · Shanghai · NCT07439757

• Preventing complications after high-risk Whipple (pancreatoduodenectomy) with hydrocortisone, octreotide, and a teres ligament patch

  This tests whether giving hydrocortisone and octreotide around surgery plus placing a teres ligament patch can lower major complications after Whipple surgery in patients with a small pancreatic duct.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07262957

• Using multi-omics markers to find invasive IPMNs

  This project tests whether combining genetic, metabolic, transcriptomic and environmental markers can help identify which adults with IPMNs have or will develop invasive pancreatic cancer.

  Recruiting IRCCS San Raffaele · Milan, MI · NCT06694792

• New biomarkers to predict which pancreatic IPMNs will progress

  This project will test whether tissue and blood biomarkers can help predict which adults with IPMN will progress to invasive pancreatic cancer.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma and 1 other locations · NCT06574373

• Innovative therapies for liver metastases in cancer patients

  This study is testing new ways to understand and treat liver tumors in patients with advanced colorectal and pancreatic cancer to see if it can lead to better therapies.

  Recruiting IRCCS San Raffaele · Milan, Milan · NCT04622423

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.